Wealth Enhancement Advisory Services LLC Lowers Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Wealth Enhancement Advisory Services LLC trimmed its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 27.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 81,247 shares of the company’s stock after selling 30,452 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Takeda Pharmaceutical were worth $1,076,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in TAK. Forum Financial Management LP increased its position in Takeda Pharmaceutical by 133.7% during the 4th quarter. Forum Financial Management LP now owns 114,324 shares of the company’s stock worth $1,514,000 after purchasing an additional 65,399 shares during the period. Toronto Dominion Bank acquired a new position in Takeda Pharmaceutical during the fourth quarter worth $6,760,000. GTS Securities LLC purchased a new position in Takeda Pharmaceutical in the fourth quarter worth $1,292,000. Vise Technologies Inc. raised its position in Takeda Pharmaceutical by 3.1% in the fourth quarter. Vise Technologies Inc. now owns 34,635 shares of the company’s stock worth $459,000 after acquiring an additional 1,026 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its holdings in Takeda Pharmaceutical by 150.6% in the fourth quarter. Voloridge Investment Management LLC now owns 340,953 shares of the company’s stock valued at $4,514,000 after acquiring an additional 204,911 shares during the period. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Down 0.2%

Shares of TAK opened at $14.97 on Monday. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.43. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $47.62 billion, a P/E ratio of 37.41, a PEG ratio of 0.24 and a beta of 0.23. The firm’s 50-day moving average is $14.66 and its two-hundred day moving average is $14.11.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The firm had revenue of $7.34 billion for the quarter, compared to analysts’ expectations of $8.02 billion. On average, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.